Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.